Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Romosozumab Benefits Osteoporosis Patients Regardless of Renal Insufficiency

Publish date:: October 23, 2019

Key clinical point: Romosozumab’s efficacy was not affected by renal insufficiency in patients with osteoporosis.

Major finding: Bone mineral density increased in all romosozumab groups regardless of estimated glomerular filtration rate (eGFR), and the risk of new vertebral fractures was decreased in all eGFR subgroups and did not appear to be affected by eGFR level.

Study details: A post hoc analysis of 7,180 postmenopausal women at various stages of renal insufficiency in the FRAME study who received romosozumab or placebo for 12 months.

Disclosures: This study was sponsored in part by Amgen, Astellas, and UCB Pharma. Dr. Miller reported receiving grants from Alexion, Amgen, Radius, Regeneron, UCB, and Ultragenyx. Amgen and UCB assisted in and provided financial assistance for the preparation of Dr. Miller’s presentation.

Citation:

Miller P et al. ASBMR 2019. Abstract 1085.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Endocrinology

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

No link shown between thyroid dysfunction and heart failure,

Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis,